Sankalp Arora
YOU?
Author Swipe
View article: Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline <scp>FLT3</scp> Inhibitor‐Based Therapy in <scp> <i>FLT3</i> </scp> ‐Mutated <scp>AML</scp>
Cytomolecular Mechanisms of Relapse and Post‐Relapse Outcomes After Frontline <span>FLT3</span> Inhibitor‐Based Therapy in <span> <i>FLT3</i> </span> ‐Mutated <span>AML</span> Open
View article: Outcomes of patients with newly diagnosed acute myeloid leukemia with <i>FLT3</i>‐tyrosine kinase domain mutations: Prognostic implications of <i>NPM1</i> co‐mutation
Outcomes of patients with newly diagnosed acute myeloid leukemia with <i>FLT3</i>‐tyrosine kinase domain mutations: Prognostic implications of <i>NPM1</i> co‐mutation Open
Background The prognostic impact of Fms‐like tyrosine kinase 3 ( FLT3 )‐tyrosine kinase domain (TKD) mutation in patients with acute myeloid leukemia (AML) is not well defined. The authors described outcomes of one of the largest cohorts o…
View article: Supplementary Table S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Baseline characteristics of patients in the frontline cohort who underwent allogeneic hematopoietic stem cell transplantation
View article: Supplementary Figure S4 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S4 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) of patients treated in the frontline cohort, stratified by TP53 status
View article: Supplementary Figure S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Study Treatment Schema
View article: Supplementary Figure S7 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S7 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) patients in the relapsed/refractory and treated secondary AML cohort stratified by prior venetoclax exposure
View article: Supplementary Figure S2 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S2 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) of transplanted patients in the frontline cohort
View article: Supplementary Figure S6 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S6 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) of patients in the relapsed/refractory and treated secondary AML cohort
View article: Supplementary Figure S8 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S8 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Quality control metrics of scRNA profiling across all cell types identified
View article: Supplementary Table S3 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S3 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Baseline characteristics and outcomes of patients with post-MPN AML
View article: Supplementary Figure S3 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S3 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Kaplan Meier estimates of event free survival (EFS) and overall survival (OS) of transplanted patients with TP53mut in the frontline cohort
View article: Supplementary Figure S5 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S5 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Response rates in the relapsed/refractory and treated-secondary AML cohort
View article: Supplementary Protocol S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Protocol S1 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Clinical Trial Protocol
View article: Supplementary Figure S10 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S10 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Distinct phenotypes in microenvironment correlated to response
View article: Supplementary Table S5 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S5 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Baseline characteristics of scRNAseq patient cohort
View article: Supplementary Table S4 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S4 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Characteristics of patients who had an Hb drop of >2 g/dL after first magrolimab infusion
View article: Supplementary Figure S9 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Figure S9 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Erythroid differentiation is a possible intrinsic resistant mechanism
View article: Data from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Data from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Purpose:Magrolimab is a monoclonal antibody directed against the macrophage checkpoint CD47 on myeloid leukemia cells that was preclinically synergistic with azacitidine–venetoclax, warranting further clinical evaluation.Patients and Metho…
View article: Supplementary Table S2 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S2 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Baseline characteristics and outcomes of patients stratified by AML ontogeny and TP53 status
View article: Supplementary Table S6 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis
Supplementary Table S6 from Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis Open
Representativeness of study participants
View article: Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma Open
View article: Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms
Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms Open
In myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with TP53 aberrations, dissecting the interaction amongst patient, disease and treatment factors are important for therapeutic decisions and prognostication. This retrospec…
View article: Adequate assessment yields appropriate care—the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group
Adequate assessment yields appropriate care—the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working Group Open
View article: Rural-urban disparities in mortality and geriatric assessment among older adults with cancer: The cancer & aging resilience evaluation (CARE) registry
Rural-urban disparities in mortality and geriatric assessment among older adults with cancer: The cancer & aging resilience evaluation (CARE) registry Open
View article: Differences in Pretreatment Frailty Across Gastrointestinal Cancers in Older Adults: Results From the Cancer and Aging Resilience Evaluation Registry
Differences in Pretreatment Frailty Across Gastrointestinal Cancers in Older Adults: Results From the Cancer and Aging Resilience Evaluation Registry Open
PURPOSE: Frailty predicts poor outcomes in older adults with cancer, but how it differs between different cancer types is unknown. We examined differences in pretreatment frailty between colorectal (CRC), pancreatic, and hepatobiliary canc…
View article: Role of Grayscale and Color Doppler Ultrasonography in Evaluation of Scrotal Pathologies
Role of Grayscale and Color Doppler Ultrasonography in Evaluation of Scrotal Pathologies Open
Aim and objective To study the spectrum of sonographic findings of various scrotal swellings and to assess the efficacy of grayscale and color Doppler sonography in the diagnosis of scrotal lesions. Materials and methods The group under st…
View article: Data-driven planning via imitation learning
Data-driven planning via imitation learning Open
Robot planning is the process of selecting a sequence of actions that optimize for a task=specific objective. For instance, the objective for a navigation task would be to find collision-free paths, whereas the objective for an exploration…
View article: Cross-sectional study about perioperative management of Blood Pressure and effects of anaesthesia in hypertensive patients undergoing general & orthopaedic surgery
Cross-sectional study about perioperative management of Blood Pressure and effects of anaesthesia in hypertensive patients undergoing general & orthopaedic surgery Open
Introduction: Hypertension is regarded as an additional risk factor during anaesthesia. There is not enough Indian evidence in literature regarding antihypertensive usage and its implications during perioperative period in patients undergo…
View article: Hindsight is Only 50/50: Unsuitability of MDP based Approximate POMDP Solvers for Multi-resolution Information Gathering
Hindsight is Only 50/50: Unsuitability of MDP based Approximate POMDP Solvers for Multi-resolution Information Gathering Open
Partially Observable Markov Decision Processes (POMDPs) offer an elegant framework to model sequential decision making in uncertain environments. Solving POMDPs online is an active area of research and given the size of real-world problems…
View article: Safe Data Gathering in Physical Spaces
Safe Data Gathering in Physical Spaces Open
Reliable and efficient acquisition of data from physical spaces has widespread applications in industry, policy, defense, and humanitarian work. Unmanned Aerial Vehicles (UAVs) are an excellent choice for data gathering applications, due t…